LEARN MORE ABOUT
MIRP THERAPIES

LEARN MORE ABOUT
MIRP THERAPIES

2023 ASCO meeting: Phase 1 dose escalation study of DSP107

a first in class CD47 and 4 1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors

DSP107 Manuscript published in JECCR

combines inhibition of CD47/ SIRPα axis with activation of 4-1BB to trigger anticancer immunity

2022 ASCO meeting: Phase 1 dose escalation study of DSP107

a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors

DSP502 – A novel approach for targeting TIGIT and PD1 pathways

SITC 2021: DSP502 Poster

DSP107 – a first in class, bifunctional, fusion protein

SITC 2019. DSP107. poster

Get in Touch

KAHR Dam HaMacbim St 28, POB 9 Modi'in Makabim-Re'ut 7178594, Israel T. +972.73.7969196 [email protected]